METiS Therapeutics (METiS), a Boston-area company integrating drug discovery and delivery with AI and machine learning,announced they have entered a collaboration with Evopoint Biosciences Co., Ltd. (“Evopoint”), a biopharmaceutical company focused on discovering and developing innovative and transformative medicines.
Recommended AI News: LZG International, Inc. (FatBrain AI) Announces Plans to Uplist to OTCQB Venture Market
Under the terms of the collaboration, METiS will receive an exclusive, worldwide, royalty-bearing license to develop and commercialize Evopoint’s SOS1 inhibitor program, a key regulatory protein/node in the RAS/MAPK pathway. SOS1 is responsible for regulating the transition of KRAS from its “off” to “on” state, making it a compelling therapeutic target. According to the National Cancer Institute (NCI), over 30% of all human cancers are driven by mutations of Ras genes. The addition of the SOS1 inhibitor program strengthens METiS’ portfolio in the RAS/MAPK space and supports the company’s broader strategy of building a targeted oncology pathway, following its September announcement of a PAN-RAF compound licensing agreement with Voronoi, Inc.
“We are excited to partner with Evopoint and accelerate the development of this potentially transformative program into a potential best-in-class asset,” Chris Lai, Co-Founder and CEO of METiS Therapeutics. “The RAS/MAPK pathway is a significant oncogenic driver, and this program fits perfectly into our strategy of shutting down this pathway and maximizing patient benefit.”
Recommended AI News: Introducing WordPress VIP for Salesforce: a Powerful, Time-saving Integration for Content Marketers
“We are thrilled to partner with METiS to leverage the therapeutic potential of the SOS1 inhibitor,” said Jason Meijie Le, CEO of Evopoint. “This collaboration underscores our shared mission to redefine and accelerate the drug development for unmet medical needs.”
Recommended AI News: Prisma Cloud Delivers Context-Aware Software Composition Analysis to Secure Deployment of Open Source Software
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.